Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer
Titel:
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer
Auteur:
Yoshioka, H. Shimokawa, M. Seto, T. Morita, S. Yatabe, Y. Okamoto, I. Tsurutani, J. Satouchi, M. Hirashima, T. Atagi, S. Shibata, K. Saito, H. Toyooka, S. Yamamoto, N. Nakagawa, K. Mitsudomi, T.